EGLN2 and prostate cancer: Furthermore, treatment with the pan-hydroxylase inhibitor DMOG suppressed cell proliferation and increased cell death across multiple prostate cancer cell lines (Figure 6C–F), recapitulating the phenotypes observed with PHD1 and PHD3 knockdown.